The stock of Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has decreased by -0.09 when compared to last closing price of 21.52.Despite this, the company has seen a gain of 0.19% in its stock price over the last five trading days. prnewswire.com reported 2024-05-09 that AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancer HAMILTON, ON and BOSTON, May 9, 2024 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 (225Ac-PSMA I&T) in patients with metastatic castration-resistant prostate cancer (mCRPC). “Actinium-based PSMA targeting RCs have demonstrated compelling safety and clinical activity, which is supported by Fusion’s encouraging data from the Phase 2 TATCIST trial reported recently at the AACR Annual Meeting.
Is It Worth Investing in Fusion Pharmaceuticals Inc (NASDAQ: FUSN) Right Now?
Company’s 36-month beta value is -0.69.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for FUSN is 67.37M, and currently, short sellers hold a 5.86% ratio of that floaft. The average trading volume of FUSN on May 24, 2024 was 1.86M shares.
FUSN’s Market Performance
The stock of Fusion Pharmaceuticals Inc (FUSN) has seen a 0.19% increase in the past week, with a 0.47% rise in the past month, and a 77.10% gain in the past quarter. The volatility ratio for the week is 0.34%, and the volatility levels for the past 30 days are at 0.44% for FUSN. The simple moving average for the last 20 days is 0.23% for FUSN’s stock, with a simple moving average of 119.95% for the last 200 days.
Analysts’ Opinion of FUSN
Many brokerage firms have already submitted their reports for FUSN stocks, with Raymond James repeating the rating for FUSN by listing it as a “Strong Buy.” The predicted price for FUSN in the upcoming period, according to Raymond James is $15 based on the research report published on December 27, 2023 of the previous year 2023.
Oppenheimer, on the other hand, stated in their research note that they expect to see FUSN reach a price target of $13. The rating they have provided for FUSN stocks is “Outperform” according to the report published on September 29th, 2023.
Raymond James gave a rating of “Outperform” to FUSN, setting the target price at $13 in the report published on June 23rd of the previous year.
FUSN Trading at 5.17% from the 50-Day Moving Average
After a stumble in the market that brought FUSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.37% of loss for the given period.
Volatility was left at 0.44%, however, over the last 30 days, the volatility rate increased by 0.34%, as shares surge +0.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +126.32% upper at present.
During the last 5 trading sessions, FUSN rose by +0.19%, which changed the moving average for the period of 200-days by +611.92% in comparison to the 20-day moving average, which settled at $21.45. In addition, Fusion Pharmaceuticals Inc saw 123.73% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for FUSN
Current profitability levels for the company are sitting at:
- -3.09 for the present operating margin
- 0.92 for the gross margin
The net margin for Fusion Pharmaceuticals Inc stands at -2.92. The total capital return value is set at -0.36. Equity return is now at value -47.11, with -35.33 for asset returns.
Based on Fusion Pharmaceuticals Inc (FUSN), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.53. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -35.05.
Currently, EBITDA for the company is -97.89 million with net debt to EBITDA at -0.34. When we switch over and look at the enterprise to sales, we see a ratio of 52.28. The receivables turnover for the company is 7.62for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.64.
Conclusion
In a nutshell, Fusion Pharmaceuticals Inc (FUSN) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
